shutterstock_1113551483_sharafmaksumov
sharafmaksumov / Shutterstock.com
12 February 2019Americas

Clarivate announces new Life Science Alliances programme

Global information company  Clarivate Analytics has launched a “Life Science Alliances Program” to provide drug and medical device developers a new way to advance their research and development.

Clarivate made the announcement in  a statement on February 7, which said the programme will aim to create a “partner ecosystem” as well as help developers in their commercialisation initiatives.

The analytics company said the programme will address some of the challenges faced by developers, such as how to quickly and efficiently access, synthesis and analyse data from a complex array of sources, by enabling greater collaboration and new capabilities among developers.

The statement also named some of the partners that have already joined the programme.

Gavin Coney, global head of life science alliances at Clarivate, said that by collaborating with Clarivate, the partners will be able to “identify, create a deliver a wide range of new capabilities that promise to accelerate the pace of innovation”.

Clarivate said it will use a technology platform called Cortellis Cloud, which it owns, to harmonise datapoints from thousands of sources on a “single, unified platform”.

According to the statement, it will be the industry’s “richest resource for data-driven insights and advanced analytics” for life science professionals.

One partner is biomedical data organisation  Bioinfogate, which will help researchers and decision makers in pharmaceutical and healthcare organisations to de-risk and optomise their research and development programmes.

The statement also named  Vitrana, a health sciences technology and consulting firm with a focus on the quality, efficiency and cost of clinical research and patient care.

Clarivate said it has partnered with Vitrana to develop a platform which delivers “specialised clinical and healthcare information management services, data transformation and smart and predictive analytics”.

Mohit Gupta, the founder and CEO of Vitrana, said that by partnering with Clarivate, Vitrana hopes to deliver “more efficient processes and novel capabilities to help life science companies successfully navigate through the most complex and evolving environment” the industry has ever experienced.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.


More on this story

Big Pharma
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.

More on this story

Big Pharma
21 March 2019   Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.